The U.S. Food and Drug Administration has granted Breakthrough Therapy designation to olomorasib, an investigational targeted therapy for adults with advanced pancreatic cancer carrying a specific genetic mutation, Eli Lilly announced Monday. The designation applies to patients whose disease has progressed after at least one prior systemic treatment and who test positive for the KRAS G12C mutation.
Pancreatic cancer remains one of the most lethal malignancies, with roughly 60,000 new diagnoses and an estimated 50,000 deaths projected annually in the United States. For those with metastatic disease, the five-year survival rate sits below 5 percent. No approved therapy currently targets KRAS G12C-mutant pancreatic cancer specifically, and emerging evidence suggests these patients may fare even worse than those without the mutation.
The FDA's Breakthrough Therapy designation is reserved for drugs that show early promise of substantial improvement over existing treatments for serious conditions. It allows for more intensive agency guidance during development and can shorten the path to approval. This marks the second such designation for olomorasib, following a September 2025 nod for its use in combination with pembrolizumab for first-line treatment of KRAS G12C-mutant non-small cell lung cancer.
Olomorasib is an oral, next-generation inhibitor designed to block the KRAS G12C protein, a driver of tumor growth. KRAS mutations are found in roughly 90 percent of pancreatic cancers, though the G12C variant specifically occurs in only about 1 to 2 percent of patients. The designation is based on encouraging preliminary data from the ongoing LOXO-RAS-20001 Phase 1/2 trial, which is evaluating the drug in advanced solid tumors, including pancreatic cancer patients who have exhausted initial therapy.
A Second Chance for a Difficult Cancer
For patients with advanced pancreatic cancer, standard care currently relies on systemic chemotherapy, with treatment choices guided by overall health. But once the disease progresses, options narrow sharply. The new designation reflects growing recognition that genomic testing at diagnosis could unlock targeted therapy opportunities for a small but desperate subset of patients.
Lilly is also studying olomorasib in multiple other KRAS G12C-driven cancers, including lung cancer, through registrational trials such as SUNRAY-01 and SUNRAY-02. The company says the drug's design allows for high potency both as a standalone treatment and in combination with other therapies.
While Breakthrough Therapy designation does not guarantee approval, it signals that regulators see meaningful potential in the data so far. The next steps involve continued enrollment in the LOXO-RAS-20001 study and further analysis of safety and efficacy. For patients with this rare mutation, the designation brings renewed hope that a targeted option may one day join the standard chemotherapy backbone, offering a more precise attack on a cancer that has historically resisted treatment.